LU91189I2 - Atazanavir sulphate et ses dérivés pharmaceutiquement acceptables (REYATAZ) - Google Patents

Atazanavir sulphate et ses dérivés pharmaceutiquement acceptables (REYATAZ)

Info

Publication number
LU91189I2
LU91189I2 LU91189C LU91189C LU91189I2 LU 91189 I2 LU91189 I2 LU 91189I2 LU 91189 C LU91189 C LU 91189C LU 91189 C LU91189 C LU 91189C LU 91189 I2 LU91189 I2 LU 91189I2
Authority
LU
Luxembourg
Prior art keywords
reyataz
pharmaceutically acceptable
acceptable derivatives
atazanavir sulphate
atazanavir
Prior art date
Application number
LU91189C
Other languages
English (en)
Other versions
LU91189I9 (fr
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27171723&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91189(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LU91189I2 publication Critical patent/LU91189I2/fr
Publication of LU91189I9 publication Critical patent/LU91189I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C07C281/04—Compounds containing any of the groups, e.g. carbazates the other nitrogen atom being further doubly-bound to a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)
LU91189C 1996-04-22 2005-08-03 Atazanavir sulphate et ses dérivés pharmaceutiquement acceptables (REYATAZ) LU91189I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH101896 1996-04-22
CH2997 1997-01-08
CH22397 1997-01-31
PCT/EP1997/001860 WO1997040029A1 (fr) 1996-04-22 1997-04-14 Derives d'azahexane heterocycliques a activite antivirale

Publications (2)

Publication Number Publication Date
LU91189I2 true LU91189I2 (fr) 2005-10-03
LU91189I9 LU91189I9 (fr) 2018-12-27

Family

ID=27171723

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91189C LU91189I2 (fr) 1996-04-22 2005-08-03 Atazanavir sulphate et ses dérivés pharmaceutiquement acceptables (REYATAZ)

Country Status (28)

Country Link
EP (1) EP0900210B1 (fr)
JP (1) JP3174347B2 (fr)
CN (3) CN1082508C (fr)
AR (1) AR006720A1 (fr)
AT (1) ATE288903T1 (fr)
AU (1) AU706183B2 (fr)
BR (1) BR9701877A (fr)
CA (3) CA2250840C (fr)
CY (1) CY2596B2 (fr)
CZ (1) CZ296135B6 (fr)
DE (2) DE122005000003I1 (fr)
DK (1) DK0900210T3 (fr)
EA (1) EA001794B1 (fr)
ES (1) ES2238720T3 (fr)
FR (1) FR05C0030I2 (fr)
HK (2) HK1018788A1 (fr)
HU (1) HU224125B1 (fr)
IL (1) IL126381A (fr)
LU (1) LU91189I2 (fr)
MY (1) MY114457A (fr)
NL (1) NL300203I2 (fr)
NO (2) NO313330B1 (fr)
NZ (3) NZ509045A (fr)
PT (1) PT900210E (fr)
SI (1) SI0900210T1 (fr)
SK (1) SK285048B6 (fr)
TW (1) TW409125B (fr)
WO (1) WO1997040029A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6251906B1 (en) 1998-05-15 2001-06-26 Abbott Laboratories Retroviral protease inhibiting compounds
EP1077977A1 (fr) * 1998-05-15 2001-02-28 Abbott Laboratories Composes inhibiteurs de proteases retrovirales
EP0976736A1 (fr) * 1998-07-29 2000-02-02 SUMIKA FINE CHEMICALS Co., Ltd. Méthode pour la production de 2-(p-alkylphényl)pyridine
EP0979820B1 (fr) 1998-08-07 2003-05-07 SUMIKA FINE CHEMICALS Co., Ltd. Dérivés de 2-phenylpyridine et leurs procédés de préparation
US6207715B1 (en) 1998-12-09 2001-03-27 American Home Products Corporation Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a substituted phenylene-diamine group
US6255349B1 (en) 1998-12-09 2001-07-03 American Home Products Corporation Alph-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group
US6197803B1 (en) 1998-12-09 2001-03-06 American Home Products Corporation Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing phenylenediamine group
US6335350B1 (en) 1998-12-09 2002-01-01 American Home Products Corporation Acetamide and substituted acetamide-containing thiourea inhibitors of herpes viruses
JP4222671B2 (ja) 1999-02-15 2009-02-12 住友化学株式会社 ヒドラジン誘導体の製造方法
IT1313664B1 (it) * 1999-10-12 2002-09-09 Norpharma S P A Processo per la preparazione di un composto aril-piridinico.
JP4278316B2 (ja) * 2000-07-14 2009-06-10 住友化学株式会社 ヒドラジン誘導体の製造方法
US6365745B1 (en) 2000-07-14 2002-04-02 Sumika Fine Chemicals Co., Ltd. Method for producing hydrazine derivative
EP1546106A1 (fr) 2002-10-02 2005-06-29 Euticals Prime European Therapeutical S.P.A Procede pour la preparation de composes d'aryl-piridyle
CA2510006C (fr) * 2002-12-06 2012-02-07 Vertex Pharmaceuticals Incorporated Compositions contenant des inhibiteurs de l'enzyme impdh
ITMI20032338A1 (it) * 2003-11-28 2005-05-29 Dinamite Dipharma S P A In Forma A Bbreviata Diph Composti feniltetrazolici.
CN1980666B (zh) * 2004-05-04 2011-03-30 布里斯托尔-迈尔斯斯奎布公司 制备阿扎那韦硫酸氢盐的方法和新的形式
CA2594395A1 (fr) 2005-02-10 2006-08-17 Medivir Ab Inhibiteurs de la protease du vih
ES2574831T3 (es) * 2006-07-21 2016-06-22 Gilead Sciences, Inc. Inhibidores de la proteasa antivirales
BRPI0823520A2 (pt) 2007-06-12 2013-12-17 Concert Pharmaceuticals Inc Composto derivado de azapeptídeos e composição farmacêutica contendo o mesmo
WO2009130534A1 (fr) * 2008-04-24 2009-10-29 Oxyrane (Pty) Ltd. Procédé de synthèse d'atazanavir
EP2272830A1 (fr) 2009-06-18 2011-01-12 Esteve Química, S.A. Procédé de préparation d'un dérivé d'azahexane hétérocyclique antiviral
EP2272831A1 (fr) 2009-06-26 2011-01-12 Prime European Therapeuticals S.p.A. Procédé pour la préparation de composés d'arylpyridinyl
WO2011037467A1 (fr) 2009-09-28 2011-03-31 Stichting Katholieke Universiteit Atazanavir pour le traitement de maladies inflammatoires
WO2011080562A1 (fr) 2009-12-29 2011-07-07 Hetero Research Foundation Nouveau aza-peptides contenant du cyclobutyl 2,2-disubstitué et/ou des dérivés alcoxy benzyle substitués comme agents antiviraux
WO2011107843A2 (fr) * 2010-03-01 2011-09-09 Lupin Limited Procédé pour la préparation de sulfate d'atazanavir sensiblement exempt de diastéréomères
EP2621472A1 (fr) 2010-09-28 2013-08-07 Ratiopharm GmbH Traitement par voie sèche de l'atazanavir
US20140343290A1 (en) * 2011-07-27 2014-11-20 Rakesh Kumar Singh Process for the preparation of atazanavir or its bisulfate salt
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
CN104250224A (zh) * 2013-06-28 2014-12-31 上海威智医药科技有限公司 阿扎那韦富马酸盐及其制备和应用
CN104163787A (zh) * 2014-08-08 2014-11-26 山东威智医药工业有限公司 阿扎那韦及其硫酸盐的制备方法
CN107459496B (zh) * 2016-06-03 2022-07-19 华东理工大学 噻唑类衍生物在治疗病毒感染中的应用
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
CN107245052A (zh) * 2017-06-21 2017-10-13 连云港杰瑞药业有限公司 一种阿扎那韦制备方法
TWI829205B (zh) 2018-07-30 2024-01-11 美商基利科學股份有限公司 抗hiv化合物
CN109251165B (zh) * 2018-10-02 2022-09-23 国药集团川抗制药有限公司 阿扎那韦达二4-氨基苯磺酸盐及其制备方法
CN109574916A (zh) * 2018-12-29 2019-04-05 常州吉恩药业有限公司 阿扎那韦中间体2-[4-(2-吡啶基)苄基]-肼羧酸叔丁酯的工业化生产方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN113603634B (zh) * 2021-08-06 2023-03-21 江苏八巨药业有限公司 一种阿扎那韦中间体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE20010533A1 (en) * 1990-11-20 2003-03-05 Abbott Lab Intermediates for preparing retroviral protease inhibiting compounds
DE59207226D1 (de) * 1991-07-03 1996-10-31 Ciba Geigy Ag Pharmakologisch wirksame Hydrazinderivate und Verfahren zu deren Herstellung
DE59303870D1 (de) * 1992-12-23 1996-10-24 Ciba Geigy Ag Antiretrovirale hydrazinderivate
DK0727419T3 (da) * 1992-12-29 2002-06-10 Abbott Lab Mellemprodukter til fremstilling af forbindelser, som inhiberer retroviral protease
US5461067A (en) * 1993-02-25 1995-10-24 Abbott Laboratories Retroviral protease inhibiting compounds

Also Published As

Publication number Publication date
HK1018788A1 (en) 2000-01-07
SI0900210T1 (fr) 2005-08-31
SK145298A3 (en) 1999-06-11
HUP9901612A3 (en) 2000-06-28
HK1075043A1 (en) 2005-12-02
EP0900210B1 (fr) 2005-02-09
CN1216539A (zh) 1999-05-12
IL126381A0 (en) 1999-05-09
NO984900L (no) 1998-12-21
HUP9901612A2 (hu) 1999-08-30
JPH11511177A (ja) 1999-09-28
PT900210E (pt) 2005-06-30
BR9701877A (pt) 1998-09-29
CN1082508C (zh) 2002-04-10
NZ509045A (en) 2002-09-27
CZ296135B6 (cs) 2006-01-11
JP3174347B2 (ja) 2001-06-11
SK285048B6 (sk) 2006-05-04
DE69732483T2 (de) 2005-07-28
CA2510945C (fr) 2007-01-16
CN1616453A (zh) 2005-05-18
AU706183B2 (en) 1999-06-10
CN1310905C (zh) 2007-04-18
EP0900210A1 (fr) 1999-03-10
ATE288903T1 (de) 2005-02-15
TW409125B (en) 2000-10-21
NZ509046A (en) 2002-05-31
EA199800899A1 (ru) 1999-10-28
CA2510945A1 (fr) 1997-10-30
AU2385997A (en) 1997-11-12
NO313330B1 (no) 2002-09-16
NL300203I2 (nl) 2005-11-01
CY2596B2 (en) 2010-03-03
NO2005010I1 (no) 2005-05-02
AR006720A1 (es) 1999-09-08
ES2238720T3 (es) 2005-09-01
CA2250840C (fr) 2006-07-04
NZ332118A (en) 2001-02-23
FR05C0030I2 (fr) 2007-04-27
HU224125B1 (hu) 2005-05-30
EA001794B1 (ru) 2001-08-27
DK0900210T3 (da) 2005-05-02
FR05C0030I1 (fr) 2005-08-12
CA2250840A1 (fr) 1997-10-30
DE69732483D1 (de) 2005-03-17
CZ337398A3 (cs) 1999-01-13
MY114457A (en) 2002-10-31
IL126381A (en) 2001-08-26
LU91189I9 (fr) 2018-12-27
DE122005000003I1 (de) 2005-05-25
NL300203I1 (nl) 2005-10-03
CA2568104A1 (fr) 1997-10-30
CN1319587A (zh) 2001-10-31
CA2568104C (fr) 2009-08-04
NO984900D0 (no) 1998-10-21
CN1193010C (zh) 2005-03-16
WO1997040029A1 (fr) 1997-10-30

Similar Documents

Publication Publication Date Title
LU91189I2 (fr) Atazanavir sulphate et ses dérivés pharmaceutiquement acceptables (REYATAZ)
LU91655I2 (fr) Corifollitropine alfa et ses dérivés pharmaceutiquement acceptables (ELONVA®)
LU91673I2 (fr) "Dronédarone et ses dérivés pharmaceutiquement acceptables (MULTAQ)"
LU91346I2 (fr) Lumiracoxib et ses dérivés pharmaceutiquement acceptables (prexige)
LU91122I2 (fr) Efalizumab et ses dérivés pharmaceutiquement acceptables (raptiva).
LU90736I2 (fr) Agenerase-amprenavir et ses d-riv-s pharmaceutiquement acceptables
LU91205I2 (fr) Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)
LU91039I2 (fr) Proteq flu et ses dérivés pharmaceutiquement acceptables
LU92381I2 (fr) Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT)
LU91269I2 (fr) Rotigotine et ses dérivés pharmaceutiquement acceptables (neupro)
NL300952I2 (nl) Peramivir en farmaceutisch aanvaardbare zouten daarvan
LU92745I2 (fr) Nétupitant/Palonosétron et leurs dérivés pharmaceutiquement acceptables (AKYNZEOr)
LU88736I2 (fr) Cefquinome et ses dérivés pharmaceutiquement acceptables (COBACTAN)
LU91163I2 (fr) Hydrobromure de darifénacine et ses dérivés pharmaceutiquement acceptables (EMSELEX.
LU92024I2 (fr) Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR)
LU88750I2 (fr) VENLAFAXINE et ses dérivés pharmaceutiquement acceptables
LU91138I2 (fr) Glulisine d'insuline et ses dérivés pharmaceutiquement acceptables.
NO985975D0 (no) Blandinger og fremgangsmÕter for frembringelse av farmakologisk aktive preparater og anvendelser derav
LU90069I2 (fr) Lercanidipine et ses sels et dérivés pharmaceutiquement acceptables (Zanidip)
LU91452I2 (fr) "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)"
LU91624I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®)
LU91076I2 (fr) Tulathromycin et ses sels pharmaceutiquement acceptables (draxxin).
LV11739A (lv) Eritromicina atvasinajumi iegusanas panemiens un pielietojums
LU91291I2 (fr) Deferasirox et ses sels pharmaceutiquement acceptables (EXJADEr)
LU91345I2 (fr) Rufinamide et ses sels pharmaceutiquement acceptables (inovelon)